Key facts
| Firm | Eugia Pharma Specialities Limited |
|---|---|
| FEI / inspection ID | 3011960448 |
| Inspection end date | February 27, 2026 |
| Citation count | 4 |
Citations explained
Observation 1 — Procedures designed to prevent microbiological contam ination of drug products purporting to
Procedures designed to prevent microbiological contam ination of drug products purporting to be sterile are not established and followed . Specificall y, 1. Environmental and personnel monitoring within the Lin~><4> j LAF are not ap5 priately established. The aseptic connection for connecting the ~><4> I vessel to (b)(4> vessel for L (b>< 4 > I mg/ml drug product is performed with in t e LAF on ( ine(b><4> ~was reclassified as Grade A-Air in July 2025 with bacterial alert and action limits of r> cfu/plate and (b> cfu/plate, respectively. The area is not held to Grade A classification during this critical operati on with a specification of No Growth. In addition, there is no immediate personnel monitoring conducted for the ind ividual after completing the aseptic connection. 2. T he ~><4> I on the sterile fill ing lines in the ~><4> blocks are 4 installed oythe operate~) (b>< > the Grade A fill ing area then \UJW n rom withi.
Observation 2 — Procedures designed to prevent microbiological contam ination of drug products purporting to
Procedures designed to prevent microbiological contam ination of drug products purporting to be sterile did not include adequate val idation of the aseptic process. Specifically, There has been no ase e!_Lc process simulation (media fill ) conducted since July 2022 for I Cb><4> mg/ ml intended for the US market, which requ ires (b><4> =:] si ng Line (b)(4) reg uires an aseptic connecti ol1ct,><4> and is usedwfi en (b)(4) cannot be (b)(4) ~ erformed on tne fil ing line. Since March 2024, at least m]6 atches o f1 I (b)(4) -7 mg/ ml have been shipped to the US market.
Observation 3 — Laboratory controls do not include the establishment of scientifica ll y sound
Laboratory controls do not include the establishment of scientifica ll y sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, qu al ity and pu rity. Specifically, Em e,!9yees engaged in visu al inspection of sterile fin ished pharmaceutical products work u:3 0 1 (b)(4) ] however, the qualificati on of the employee is only performed after ~><4> of visual 1nspect1on the first time the employee is qu al ifi ed to perform visu al inspection an d is not performed again at subsequent requalifications. Of the (b)(4) employees qualified for visual inspecti on , ~><4> , ere first qualified in ~><4> Jwere first qu al ified irl(b~-;-i an~(b><4>l were first qualified i n(b><4> with the remainder first qu al ified more recently, and none were chal le ng ed after ~><4> since their first qualification. EMPLOYE E($) SIGNATURE SEE REVERSE Matthew B Casale, I nves t iga t or -.
Observation 4 — There is a failure to thoroughly review any unexplained discrepancy and the
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the bat ch has been already distribu t ed . Specifically, Investigations into issues requiring the fil ing of Field Alert Reports are not always complete. For example, 1. Investigation MC- EP1 -24-0107 was opened on 06/06/2024 due to a consumer complaint of an 18 mm glass t ece found in a dispensed vial of ~><4> ii lnjecti on , USP(b)(4) mg per (b)(4) ml batch ~(b)(4) I The investigat ion could not fina he source of thk glass; however the roo cause was attribu ted to vials breaking in the ~><4> ] and leaving glass in intact vials. Corrective actions to the investIgat 1on included adding new preventative maintenance to the ~><4> I4 r Cbx >7 , adding a review of (b)(4) I rejected vials, and ada ing a.
What a Form 483 means
A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.
Eugia Pharma Specialities Limited’s FDA history
Argus HQ has recorded 2 total FDA actions tied to Eugia Pharma Specialities Limited: 0 warning letters, 0 recalls, 0 approval records, and 2 Form 483 inspection citations.
Frequently asked questions
- Does this Form 483 mean Eugia Pharma Specialities Limited violated the law?
- No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
- What happens after a Form 483 is issued?
- The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.
- Has Eugia Pharma Specialities Limited had other FDA inspection citations?
- Yes. Argus HQ has recorded 2 total FDA actions tied to Eugia Pharma Specialities Limited, including 2 Form 483 inspection citations.
- What is the FEI / inspection ID for this Form 483?
- FEI / inspection ID: 3011960448.
See if this 483 escalates to a warning letter — before your auditor asks.
Free weekly briefing tracks every FDA inspection outcome.
Related enforcement actions
Full FDA history for Eugia Pharma Specialities LimitedCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Inspects Eugia Pharma Specialities Limited: Form 483 with 4 Citations (February 27, 2026). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-eugia-pharma-specialities-limited-2026-02-27-3011960448
"FDA Inspects Eugia Pharma Specialities Limited: Form 483 with 4 Citations (February 27, 2026)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/483/fda-483-eugia-pharma-specialities-limited-2026-02-27-3011960448.
Argus HQ Research. "FDA Inspects Eugia Pharma Specialities Limited: Form 483 with 4 Citations (February 27, 2026)." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-eugia-pharma-specialities-limited-2026-02-27-3011960448.
@misc{argushq_argushq_ai_483_fda_483_eugia_pharma_specialities_limited_2026_02_27_3011960448_2026,
title = {FDA Inspects Eugia Pharma Specialities Limited: Form 483 with 4 Citations (February 27, 2026)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/483/fda-483-eugia-pharma-specialities-limited-2026-02-27-3011960448},
note = {Accessed: July 15, 2026}
}